Novavax begins early-stage trial for flu-Covid combo vaccine

Vaccine developer Novavax Inc said today it has initiated an early-stage study to test its combined flu and Covid-19 vaccine. The trial, to be conducted in Australia, will enrol 640 healthy adults between the ages of 50 and 70 years and who have either been previously infected with the coronavirus or given an authorized Covid-19 vaccine at least eight weeks prior to the study.